Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. Viewhere

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksERGO.L Regulatory News (ERGO)

  • There is currently no data for ERGO

Block Listing Six Monthly Return

2 Jan 2019 07:00

RNS Number : 7694L
Ergomed plc
02 January 2019
 

BLOCK LISTING SIX MONTHLY RETURN

 

 

Date: 2 January 2019

 

Name of applicant:

Ergomed plc

Name of scheme:

Ergomed plc Long Term Incentive Plan

Period of return:

From:

2 July 2018

To:

31 December 2018

Balance of unallotted securities under scheme(s) from previous return:

1,800,000 (original admission)

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

nil

Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

55,000

Equals: Balance under scheme(s) not yet issued/allotted at end of period:

1,745,000

Number and class of securities originally admitted and the date of admission

1,800,000 ordinary shares of 1p each - 2 July 2018

Total number of securities in issue at the end of the period

45,016,438 ordinary shares of 1p each

 

Name of contact:

Nick Blech - Deputy CFO

Telephone number of contact:

+44 (0)7768 547372

 

 Enquiries:

Ergomed plc

Tel: +44 (0) 1483 503205

Stephen Stamp (Chief Executive Officer)

Stuart Jackson (Chief Financial Officer)

 

Numis Securities Limited

Tel: +44 (0) 20 7260 1000

Michael Meade / Freddie Barnfield (Nominated Adviser)

James Black (Broker)

 

Consilium Strategic Communications - for UK enquiries

Tel: +44 (0) 20 3709 5700

Chris Gardner / Mary-Jane Elliott

Matthew Neal / Olivia Manser

 

ergomed@consilium-comms.com

MC-Services - for Continental European enquiries

Tel: +49 211 5292 5222

Anne Hennecke

 

About Ergomed plc

Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing, profitable services offering encompasses a complete suite of specialist pharmacovigilance solutions, integrated under the PrimeVigilance brand, in addition to a full range of high quality contract research and trial management services (CRO). Leveraging its CRO expertise, Ergomed also has a drug development portfolio of co-development partnerships and wholly-owned programmes. For further information, visit: http://ergomedplc.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
BLRFEWFWAFASEEE
Date   Source Headline
1st Mar 20217:00 amRNSTotal Voting Rights
25th Feb 20218:42 amRNSHolding(s) in Company
10th Feb 20217:00 amRNSNotice of Preliminary Results
26th Jan 20218:42 amEQSErgomed (ERGO): PrimeVigilance excels; CRO strengthened in US
26th Jan 20217:00 amRNSErgomed 2020 Trading Update
4th Jan 20217:00 amRNSTotal Voting Rights and Block Listing Return
15th Dec 20208:00 amEQSErgomed (ERGO): MedSource acquisition to boost US CRO business
14th Dec 20207:00 amRNSAcquisition of MedSource
24th Nov 20204:34 pmRNSHolding(s) in Company
18th Nov 20207:00 amRNSShare Capital Reduction Effective
11th Nov 20207:00 amRNSErgomed to Present at Jefferies Conference
2nd Nov 20207:00 amRNSTotal Voting Rights
21st Oct 20205:26 pmRNSHolding(s) in Company
19th Oct 202010:12 amRNSResult of General Meeting
12th Oct 20205:51 pmRNSHolding(s) in Company
1st Oct 20207:00 amRNSTotal Voting Rights
1st Oct 20207:00 amRNSProposed Capital Reduction
23rd Sep 20207:06 amRNSSecond Price Monitoring Extn
23rd Sep 20207:03 amRNSPrice Monitoring Extension
22nd Sep 20204:40 pmRNSSecond Price Monitoring Extn
22nd Sep 20204:35 pmRNSPrice Monitoring Extension
22nd Sep 20207:00 amRNSInterim Results
9th Sep 20201:50 pmRNSHolding(s) in Company
1st Sep 20207:00 amRNSTotal Voting Rights
20th Aug 202011:32 amRNSHolding(s) in Company
20th Aug 20207:00 amRNSNotice of Interim Results
14th Aug 20204:19 pmRNSHoldings in Company
4th Aug 20207:00 amRNSExercise of Share Options and Total Voting Rights
3rd Aug 20207:00 amRNSTotal Voting Rights
23rd Jul 20201:02 pmRNSHoldings in Company
22nd Jul 202012:57 pmRNSHolding(s) in Company
21st Jul 20202:14 pmRNSHoldings in Company
21st Jul 20202:13 pmRNSHoldings in Company
21st Jul 20207:00 amRNSErgomed H1 2020 Trading Update
20th Jul 20205:35 pmRNSHolding(s) in Company
20th Jul 20202:08 pmRNSHolding(s) in Company
17th Jul 202012:19 pmRNSHolding(s) in Company
15th Jul 202012:03 pmRNSHolding(s) in Company
6th Jul 20204:14 pmRNSExercise of Share Options and Total Voting Rights
1st Jul 20207:00 amRNSTotal Voting Rights & Block Listing Return
29th Jun 20205:17 pmRNSHoldings in Company
10th Jun 20201:43 pmEQSEdison Inv Research Limited: Edison issues flash on Ergomed (ERGO)
10th Jun 202010:53 amRNSResult of AGM
10th Jun 20207:00 amRNSAnnual General Meeting Statement
1st Jun 20207:00 amRNSTotal Voting Rights
28th May 20207:00 amRNSErgomed to Present at Jefferies Conference
18th May 20207:00 amRNSStrategic Partnership in Intelligent Automation
15th May 20207:00 amRNSNotice of AGM and Annual Report and Board Changes
1st May 20207:00 amRNSTotal Voting Rights
6th Apr 20207:00 amRNSErgomed Announces Second COVID-19 Clinical Study

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.